Back to search

University of Patras

Check point inhibitors και η επίδρασή τους στο ανοσοποιητικό σύστημα-μεταβολές στους Β κυτταρικούς υποπληθυσμούς μετά από θεραπεία

Abstract

dc:description

Introduction: Globally the efforts to find the best cancer treatment are demanding and very intensive. Immunotherapy has gained an important role as second or sometimes first line of treatment for various types of cancer. PD-1/ PD-L1 checkpoint inhibitors are an impending category of immunotherapy and their mechanism, as well as their interaction with T cells, are well studied. However, our knowledge about any possible effect(s) of immunotherapy on B cells is limited. In this prospective study, we asked the question of any possible alterations of circulating B cells (numbers and subsets) occurring during immunotherapy in patients with cancer and of the potential correlation of such changes with the outcomes and with development of immune-related adverse events (irAEs).Methods: We enrolled 20 cancer patients who received PD-1 checkpoint inhibitors and 8 healthy donors (HD). Patients underwent regular clinical assessment and imaging using the iRECIST criteria for 6 months following immunotherapy. Peripheral blood samples were collected before and during PD-1 checkpoint inhibitor therapy and flow cytometry analysis of peripheral blood mononuclear cells (PBMCs) was performed evaluating various circulating B cell subset phenotypes, including mature naïve B cells, memory B cells, regulatory B cells (Bregs), antibody-secreting cells (ASCs), and age-related B cells (ABCs). Statistical analysis was employed to compare the differences of B cells between different groups and among sequential data within the same group. Results: Total circulating CD19+ B cell counts remained stable across both groups [responders (R), non-responders(NR)] and timepoints. However, there was a significant rise of mature naïve B cells and decline of memory B cells at the initiation of the treatment in the R group compared to healthy donors and to the NR group. Such changes were correlated with a good response to immunotherapy. On the contrary, higher numbers of ABCs at baseline were seen in the NR group and were correlated with resistance to treatment. As far as immune-related adverse events are concerned, no significant changes were recorded among the different B cell subpopulations evaluated in both groups. Discussion: Our study provides preliminary data suggesting that B cell subset changes during immunotherapy may correlate with immune checkpoint inhibitor-induced clinical responses in patients with neoplasia. Further investigations to delineate the potential role(s) of B cells in patients undergoing immunotherapy is needed.

Degree

thesis:*
Grantor dc:publisher
University of Patras
Year dc:date
2024

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Pouliasi, Foteini
  • Πουλιάση, Φωτεινή

Subjects

dc:subject × 17

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/58546

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Pouliasi, Foteini; Πουλιάση, Φωτεινή. Check point inhibitors και η επίδρασή τους στο ανοσοποιητικό σύστημα-μεταβολές στους Β κυτταρικούς υποπληθυσμούς μετά από θεραπεία. University of Patras, 2024. http://hdl.handle.net/10442/hedi/58546